Drug Profile
IMAB 027
Alternative Names: ASP-1650; IMAB-027Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Ganymed Pharmaceuticals
- Developer Astellas Pharma; Ganymed Pharmaceuticals
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Germ cell cancer; Ovarian cancer; Testicular cancer
Most Recent Events
- 11 Aug 2023 Discontinued - Phase-I/II for Ovarian cancer (Late-stage disease) in Belgium, Ukraine, Russia, Germany (IV) prior to August 2023 (Astellas Pharma pipeline, August 2023)
- 11 Aug 2023 Discontinued - Phase-II for Germ cell cancer (Late-stage disease, Second-line therapy or greater) in USA (IV) prior to August 2023 (Astellas Pharma pipeline, August 2023)
- 02 Jan 2023 No development reported - Phase-II for Germ cell cancer (Late-stage disease, Second-line therapy or greater) in USA (IV)